Cyclobenzaprine hydrochloride, USP

/Cyclobenzaprine hydrochloride, USP
Cyclobenzaprine hydrochloride, USP2018-09-06T09:12:40+00:00

Prescription Drug Name:

Cyclobenzaprine hydrochloride, USP

ID:

6b65c4ae-4ddc-0678-e053-2a91aa0a01ef

Code:

34391-3

DESCRIPTION


id: 6b658f98-d6c0-9ac9-e053-2991aa0ab3b0
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Cyclobenzaprine hydrochloride, USP is a white, crystalline tricyclic amine salt with the molecular formula C
20H
21N • HCl and a molecular weight of 311.9. It has a melting point of 217°C, and a pKa of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine hydrochloride is designated chemically as 3-(5H -dibenzo[a,d] cyclohepten-5-ylidene)-N, N-dimethyl-1-propanamine hydrochloride, and has the following structural formula:
Cyclobenzaprine hydrochloride tablets, USP are available as 5 mg and 10 mg tablets for oral administration. Cyclobenzaprine hydrochloride tablets USP contain the following inactive ingredients: colloidal silicon dioxide, corn starch, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and propylene glycol.

CLINICAL PHARMACOLOGY


id: 6b658f98-d6c1-9ac9-e053-2991aa0ab3b0
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

Cyclobenzaprine hydrochloride relieves skeletal muscle spasm of local origin without interfering with muscle function. It is ineffective in muscle spasm due to central nervous system disease. Cyclobenzaprine reduced or abolished skeletal muscle hyperactivity in several animal models. Animal studies indicate that cyclobenzaprine does not act at the neuromuscular junction or directly on skeletal muscle. Such studies show that cyclobenzaprine acts primarily within the central nervous system at brain stem as opposed to spinal cord levels, although its action on the latter may contribute to its overall skeletal muscle relaxant activity. Evidence suggests that the net effect of cyclobenzaprine is a reduction of tonic somatic motor activity, influencing both gamma (γ) and alpha (α) motor systems. Pharmacological studies in animals showed a similarity between the effects of cyclobenzaprine and the structurally related tricyclic antidepressants, including reserpine antagonism, norepinephrine potentiation, potent peripheral and central anticholinergic effects, and sedation. Cyclobenzaprine caused slight to moderate increase in heart rate in animals.

INDICATIONS AND USAGE


id: 6b658f98-d6c7-9ac9-e053-2991aa0ab3b0
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.

CONTRAINDICATIONS


id: 6b658f98-d6c8-9ac9-e053-2991aa0ab3b0
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Hypersensitivity to any component of this product. Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs. Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. Hyperthyroidism.

ADVERSE REACTIONS


id: 6b658f98-d6d6-9ac9-e053-2991aa0ab3b0
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Incidence of most common adverse reactions in the two double-blind, placebo-controlled 5 mg studies (incidence of > 3% on cyclobenzaprine hydrochloride 5 mg):

  Cyclobenzaprine

Hydrochloride 5 mg

Cyclobenzaprine

Hydrochloride 10 mg

Placebo
  N = 464 N = 249 N = 469
Drowsiness 29% 38% 10%
Dry Mouth 21% 32% 7%
Fatigue 6% 6% 3%
Headache 5% 5% 8%
Adverse reactions which were reported in 1% to 3% of the patients were: abdominal pain, acid regurgitation, constipation, diarrhea, dizziness, nausea, irritability, mental acuity decreased, nervousness, upper respiratory infection, and pharyngitis. The following list of adverse reactions is based on the experience in 473 patients treated with cyclobenzaprine hydrochloride 10 mg in additional controlled clinical studies, 7607 patients in the post-marketing surveillance program, and reports received since the drug was marketed. The overall incidence of adverse reactions among patients in the surveillance program was less than the incidence in the controlled clinical studies. The adverse reactions reported most frequently with cyclobenzaprine were drowsiness, dry mouth and dizziness. The incidence of these common adverse reactions was lower in the surveillance program than in the controlled clinical studies:
  Clinical Studies with

Cyclobenzaprine

Hydrochloride 10 mg

Surveillance Program with

Cyclobenzaprine

Hydrochloride 10 mg

Drowsiness 39% 16%
Dry Mouth 27% 7%
Dizziness 11% 3%
Among the less frequent adverse reactions, there was no appreciable difference in incidence in controlled clinical studies or in the surveillance program. Adverse reactions which were reported in 1% to 3% of the patients were: fatigue/tiredness, asthenia, nausea, constipation, dyspepsia, unpleasant taste, blurred vision, headache, nervousness, and confusion. The following adverse reactions have been reported in post-marketing experience or with an incidence of less than 1% of patients in clinical trials with the 10 mg tablet: Body as a Whole: Syncope; malaise. Cardiovascular: Tachycardia; arrhythmia; vasodilatation; palpitation; hypotension. Digestive: Vomiting; anorexia; diarrhea; gastrointestinal pain; gastritis; thirst; flatulence; edema of the tongue; abnormal liver function and rare reports of hepatitis, jaundice and cholestasis. Hypersensitivity: Anaphylaxis; angioedema; pruritus; facial edema; urticaria; rash. Musculoskeletal: Local weakness. Nervous System and Psychiatric: Seizures; ataxia; vertigo; dysarthria; tremors; hypertonia; convulsions; muscle twitching; disorientation; insomnia; depressed mood; abnormal sensations; anxiety; agitation; psychosis; abnormal thinking and dreaming; hallucinations; excitement; paresthesia; diplopia, serotonin syndrome. Skin: Sweating. Special Senses: Ageusia; tinnitus. Urogenital: Urinary frequency and/or retention.

DRUG ABUSE AND DEPENDENCE


id: 6b658f98-d6d8-9ac9-e053-2991aa0ab3b0
displayName: DRUG ABUSE AND DEPENDENCE SECTION
FDA Article Code: 42227-9

Pharmacologic similarities among the tricyclic drugs require that certain withdrawal symptoms be considered when cyclobenzaprine hydrochloride is administered, even though they have not been reported to occur with this drug. Abrupt cessation of treatment after prolonged administration rarely may produce nausea, headache, and malaise. These are not indicative of addiction.

OVERDOSAGE


id: 6b658f98-d6d9-9ac9-e053-2991aa0ab3b0
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

Although rare, deaths may occur from overdosage with cyclobenzaprine hydrochloride. Multiple drug ingestion (including alcohol) is common in deliberate cyclobenzaprine overdose.
As management of overdose is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. Signs and symptoms of toxicity may develop rapidly after cyclobenzaprine overdose; therefore, hospital monitoring is required as soon as possible. The acute oral LD
50 of cyclobenzaprine hydrochloride is approximately 338 and 425 mg/kg in mice and rats, respectively.

DOSAGE AND ADMINISTRATION


id: 6b658f98-d6e2-9ac9-e053-2991aa0ab3b0
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Use of cyclobenzaprine hydrochloride tablets for periods longer than 2 or 3 weeks is not recommended (see INDICATIONS AND USAGE). Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS, Impaired Hepatic Function, and Use in the Elderly).

HOW SUPPLIED


id: 6b6603f0-ec75-159b-e053-2a91aa0a0553
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Cyclobenzaprine Hydrochloride Tablets, USP, 5 mg tablets are capsule-shaped, white, film coated tablets, debossed MP 578 on one side and plain on the other side NDC 68071-4415-2 BOTTLES OF 12 NDC 68071-4415-4 BOTTLES OF 14 NDC 68071-4415-1 BOTTLES OF 21 NDC 68071-4415-3 BOTTLES OF 30 NDC 68071-4415-6 BOTTLES OF 60 NDC 68071-4415-9 BOTTLES OF 90 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER. Manufactured by:

Frontida BioPharm, Inc

Philadelphia, PA 19124 Distributed by:

TruPharma, LLC

Tampa, FL 33609 Rev00, April 2017

PRINCIPAL DISPLAY PANEL


id: 6b6603f0-ec78-159b-e053-2a91aa0a0553
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4